SCHEMBL1505762

SCHEMBL1505762

CCNC(=O)Cc1cc(Nc2cccc(OC(F)(F)F)c2)nn1-c1cc(C)nc(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GALR2 O43603 2/20 0.40
▸ GALR1 P47211 1/20 0.40
▸ NPY5R Q15761 1/20 0.40
▸ BRAF P15056 1/20 0.40
▸ IGF1R P08069 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ P2RX3 P56373 3/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ PIM1 P11309 1/20 0.37
▸ SCN9A Q15858 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506231 0.91 MAPK1 (0.45) GALR2GALR1NPY5RBRAFIGF1R
SCHEMBL1505927 0.91 SYK (0.42) GALR2GALR1NPY5RBRAFIGF1R
SCHEMBL1506125 0.90 MAPK1 (0.42) GALR2GALR1NPY5RBRAFIGF1R
SCHEMBL1506116 0.89 CYP3A4 (0.45) GALR2GALR1NPY5RBRAFPIM1
SCHEMBL1506088 0.88 GALR2 (0.42) GALR2GALR1NPY5RBRAFIGF1R
SCHEMBL10009094 0.88 GALR2 (0.41) GALR2GALR1NPY5RBRAFPIM1
SCHEMBL10010866 0.82 MAPK1 (0.46) GALR2GALR1NPY5RBRAFIGF1R
SCHEMBL1506340 0.81 CYP2D6 (0.46) NPY5RBRAFMAPK1PIM1CYP3A4
SCHEMBL10009161 0.81 MAPK1 (0.50) GALR2GALR1NPY5RBRAFIGF1R
SCHEMBL1506166 0.81 IGF1R (0.41) GALR2GALR1NPY5RIGF1RP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574832-B Substituted N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV 2014-09-24 — — CN disclosed
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 GALR2 201/4885GALR1 89/4885NPY5R 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback